Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | DDR2 | Q16832 | 5/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599948 | 0.91 | CDK8 (0.62) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13199966 | 0.89 | MAPK14 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600103 | 0.89 | CDK8 (0.62) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600918 | 0.89 | MAPK14 (0.68) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1599903 | 0.88 | CDK8 (0.58) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13200908 | 0.87 | SMN1; SMN2 (0.56) | GAASMN1; SMN2 | |
| SCHEMBL1599299 | 0.87 | MAPK14 (0.63) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13199967 | 0.87 | MAPK14 (0.61) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1599975 | 0.86 | CDK8 (0.58) | CDK8MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1600182 | 0.85 | CDK8 (0.60) | CDK8MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | CDK8 2519/4885MAPK14 2884/4885MAPK13 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.